Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486895 · ClinicalTrials.gov registry record · Phase 1
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
A Phase 1 study of Healthy Adult Participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT07486895 is a Phase 1 study of Healthy Adult Participants that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 44 participants, below the 69-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07486895, a Phase 1 study of Healthy Adult Participants, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.
Conditions Studied
Interventions
- DRUG Centanafadine
Study Locations (1)
Kansas
- ICON plc - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486895
The ClinicalTrials.gov registry entry for NCT07486895 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (36% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 1 intervention - of which Centanafadine is the first listed.
NCT07486895 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT07486895 about?
NCT07486895 is a clinical study titled "Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects". The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.
What is the current status of trial NCT07486895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-03-08. Estimated completion is 2023-05-18.
What conditions does trial NCT07486895 study?
This clinical trial studies the following conditions: Healthy Adult Participants.
What interventions are being tested in trial NCT07486895?
The interventions under investigation include: Centanafadine (DRUG).
Who is sponsoring clinical trial NCT07486895?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07486895 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
RECRUITING · Phase 1
-
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
RECRUITING · Phase 1
-
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.